Opioid Patients’ Right to Know Act of 2021
Bill: H.R.1185 | Sponsor: Rep. Trone, David J. (D-MD)
Policy area: Health

Summary:
Opioid Patients' Right to Know Act of 2021
This bill requires the Centers for Disease Control and Prevention to award grants to states to educate health care providers about opioid prescribing practices.
To receive a grant, a state must have a law or regulation that requires providers to, before issuing an initial opioid prescription to treat acute pain, inform patients about the risks of opioids and the availability of non-opioid treatment alternatives.
States must use the grants to educate providers about relevant laws or regulations and safe opioid prescribing recommendations.

To amend the Public Health Service Act to authorize grants to certain 
    States to inform patients about the risks of opioids and their 
                   analogues, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Opioid Patients' Right to Know Act 
of 2021''.

SEC. 2. GRANT PROGRAM TO INFORM PATIENTS ABOUT THE RISKS OF OPIOIDS AND 
              THEIR ANALOGUES.

    Part J of title III of the Public Health Service Act (42 U.S.C. 
280b et seq.) is amended by inserting after section 392A (42 U.S.C. 
280b-1) the following:

``SEC. 392B. GRANT PROGRAM TO INFORM PATIENTS ABOUT THE RISKS OF 
              OPIOIDS AND THEIR ANALOGUES.

    ``(a) In General.--The Secretary, acting through the Director of 
the Centers for Disease Control and Prevention, shall award one grant 
(over the life of the program under this section) to each eligible 
State to inform covered health care providers about--
            ``(1) the requirement of the State described in subsection 
        (b); and
            ``(2) recommendations for safe opioid prescribing.
    ``(b) Eligibility.--To be eligible to receive a grant under 
subsection (a), a State must have in effect a law or regulation 
requiring covered health care providers, before issuing a new 
prescription for a covered drug or analogue, to inform the patient 
involved, and the patient's guardian if the patient has a guardian, 
about--
            ``(1) the risks of such covered drug or analogue;
            ``(2) the addictive qualities of such covered drug or 
        analogue; and
            ``(3) non-opioid treatments to such covered drug or 
        analogue, as appropriate.
    ``(c) Grant Amount.--The amount of a grant to a State under this 
section--
            ``(1) shall be greater than the amount of each grant to a 
        State with a smaller number of covered health providers, as 
        estimated by the Secretary;
            ``(2) shall not exceed $1,000,000; and
            ``(3) subject to the availability of funds, shall not be 
        less than $750,000.
    ``(d) Definitions.--For purposes of this section:
            ``(1) Covered drug or analogue.--The term `covered drug or 
        analogue' means a drug that is or contains an opioid (as 
        defined in section 102 of the Controlled Substances Act) or an 
        analogue of an opioid.
            ``(2) Covered health care provider.--The term `covered 
        health care provider' means a health care provider who issues 
        prescriptions for a covered drug or analogue for the relief of 
        acute pain.
    ``(e) Authorization of Appropriations.--There is authorized to be 
appropriated to carry out this section $10,000,000 for each of fiscal 
years 2022 through 2031.''.
                                 <all>